Healthcare
3SBio Inc.(TRSBF)
Live Price
Offline$2.20
+0.00% today
Window Change
-13.73%
Window
May 29, 2026 β Jun 12, 2026
- Market Cap
- $49.45B
- Revenue Growth
- +89.3%
- EPS Growth
- +298.8%
- Dividend Yield
- 1.1%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 11 bars Β· May 29, 2026 β Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
3SBio Inc. (TRSBF) is a Healthcare stock with a market cap of $49.45B and listed on OTC. The stock last traded around $2.20 and down 13.7% across the available one-year price window (May 29, 2026 β Jun 12, 2026). Baseline metrics include revenue growth of +89.3%, EPS growth of +298.8%, a dividend yield of 1.1%. What stands out right now is revenue +89.3%, EPS +298.8%, free cash flow +307.8% with operating margin 59.6% and ROIC 26.1%. The dividend is present but secondary, with a yield around 1.1%. Valuation is more restrained than many high-expectation growth names at P/E 5.7 and price/sales 2.8. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines TRSBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+89.3% vs +7.6% peer median
Operating Margin
Above sector median
+59.6% vs +19.4% peer median
P/E
Below sector median
5.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Mar 30, 2026 with an EPS surprise of -19.5% and a revenue surprise of -3.5%.
The operating story is still moving forward
Revenue is running at +89.3% and EPS at +298.8%, with operating margin around 59.6%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 26, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRSBF
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
TRSBF Max Drawdown
-21.57%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TRSBF and SPY.
Company Overview
3SBio Inc.
Other OTC
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaΒFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
- Leadership
- Jing Lou
- IPO Date
- Jun 26, 2018
- Employees
- 5.6k
- Street Address
- No. 3 A1, Road 10
- Mailing
- Shenyang, 110027
- Region
- Shenyang, CN
- Reporting Currency
- USD
- Investor Line
- 86 24 2538 6000
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 5.7
- EV/EBITDA
- 3.7
- Price/Sales
- 2.8
- Price/Book
- 1.8
Growth
- Revenue
- +89.3%
- EPS
- +298.8%
- Free Cash Flow
- +307.8%
Profitability
- Gross Margin
- 92.4%
- Operating Margin
- 59.6%
- Net Margin
- 47.9%
- ROE
- 38.4%
- ROIC
- 26.1%
Balance Sheet
- Debt/Equity
- 0.10
- Current Ratio
- 5.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.